RxDoctor Payments Data

Sarah Marquez, MD

Internal Medicine · Mission Hills, CANPI 1154854826

Payments from drug & device makers

$1,370in general payments, 2019–2025

Across 37 payments — averaging $37.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$610
  • Novo Nordisk$128
  • Johnson & Johnson$119
  • Janssen Scientific Affairs, LLC$104
  • Merck$84
  • GSK$56
  • plus $268 from 8 others

What the payments were for

  • Food & beverage$1,370100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,370 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$16,307
Medicare patients
65
Services billed
235

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide46$72,244
FarxigaDapagliflozin Propanediol49$51,402
EliquisApixaban32$26,614
JanuviaSitagliptin Phosphate26$22,551
MounjaroTirzepatide15$22,539
TrulicityDulaglutide12$18,535
JardianceEmpagliflozin12$17,810
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$10,992
Atorvastatin Calcium417$4,713
Losartan Potassium194$2,722
Levothyroxine Sodium132$2,223
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$1,412
Metoprolol Succinate72$1,339
Levetiracetam16$1,193
Gabapentin79$1,160

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$128$72,24446 claims
MerckJanuvia$84$22,55126 claims
Boehringer IngelheimJardiance$17$17,81012 claims
GSKTrelegy Ellipta$56$10,99211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Mission Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →